{
  "pmcid": "8183183",
  "abstract": "300-word version:\n\nTitle: Randomised Controlled Trial Comparing Morbidity of Local Excision and Total Mesorectal Excision after Neoadjuvant Chemoradiotherapy for Low Rectal Cancer\n\nBackground: This study aimed to compare early and late morbidity between local excision (LE) and total mesorectal excision (TME) following neoadjuvant chemoradiotherapy in patients with low rectal cancer.\n\nMethods: In this post-hoc analysis of the GRECCAR2 randomised trial, patients with clinical T2/T3 low rectal cancer showing a good response to chemoradiotherapy were randomised to LE or TME. The primary outcome was surgical morbidity, assessed at 1 month (early) and 2 years (late) post-surgery. Randomisation was performed centrally, and allocation was concealed. Blinding was not applicable. Between March 2007 and September 2012, 148 patients were randomised: 74 to LE and 74 to TME. Intention-to-treat analysis was conducted on 145 patients.\n\nResults: Early surgical morbidity was significantly lower in the LE group (20%) compared to TME (36%) and completion TME (43%) (P = 0.025). Late surgical morbidity was also lower in the LE group (4%) compared to TME (33%) and completion TME (57%) (P < 0.001). No deaths occurred in any group. LE was associated with fewer medical morbidities, though not statistically significant. The severity of overall morbidity was significantly lower at 2 years after LE compared with TME or completion TME (4% vs. 28% vs. 43% grade 3â€“5, P < 0.001).\n\nInterpretation: LE demonstrated significantly lower early and late surgical morbidity compared to TME, supporting its use as a safe organ-preserving alternative in selected patients. The findings suggest LE as a viable option for organ preservation in complete clinical responders and as an alternative to TME in subcomplete responders. Trial registration: NCT00427375. Funding: National Cancer Institute of France.",
  "word_count": 279
}